-
T2 Biosystems (TTOO) and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform
-
T2 Biosystems (TTOO) Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
-
T2 Biosystems (TTOO) Announces Preliminary Third Quarter 2024 Financial Results
-
T2 Biosystems (TTOO) Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the EU
-
T2 Biosystems (TTOO) Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
-
T2 Biosystems, Inc (TTOO) PT Raised to $5 at Canaccord Genuity
-
T2 Biosystems (TTOO) Misses Q2 EPS by 66c
-
T2 Biosystems (TTOO) Announces Commercial Expansion Through Malaysia and Indonesia Distributor
-
T2 Biosystems (TTOO) Files $150M Mixed Shelf
-
T2 Biosystems (TTOO) Announces Commercial Expansion Through Hong Kong and Macau Distributor

